3-Iodobenzylguanidine clinical trials
Also written 131I-MIBG.
How each study uses 3-Iodobenzylguanidine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the 3-Iodobenzylguanidine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 11
David Bushnell (2) · Molecular Insight Pharmaceuticals, Inc. (2) · Nationwide Children's Hospital (1) · Masonic Cancer Center, University of Minnesota (1) · Cancer Research UK (1) · University of California, San Francisco (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Cold Contaminant-free Iobenguane I-131 (2) · Edotreotide yttrium y-90 (1) · Fludarabine (1) · Thiotepa (1) · Rituximab (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test 3-Iodobenzylguanidine.
- May 2027Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or ParagangliomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Sep 2027MIBG in Aging and Neurologic DisordersPhase 4 · Mayo Clinic
Studies
Open first, then newest update. How each study uses 3-Iodobenzylguanidine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- MIBG in Aging and Neurologic DisordersEnrolling by invitationPhase 4Mayo ClinicNCT05514106Written as meta-iodobenzylguanidine (MIBG) (123I)How we know
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or ParagangliomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT00107289Written as iobenguane I 131How we know
- MIBG for Refractory Neuroblastoma and PheochromocytomaCompletedNot applicableMasonic Cancer Center, University of MinnesotaNCT01850888Written as 131 I-Metaiodobenzylguanidine (131I-MIBG)How we know
- MIBG Therapy for Patients With MIBG Avid TumorsActive, not recruitingPhase 2Nationwide Children's HospitalNCT02378428Written as MIBGHow we know
- A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine TumorsWithdrawnPhase 1/2David BushnellNCT04614766Written as AzedraHow we know
- Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine TumorsActive, not recruitingEarly Phase 1David BushnellNCT03044977Written as 131I-MIBGHow we know
- A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma SubjectsStatus unknownPhase 2Jubilant DraxImage Inc.NCT03561259Written as 131I-MIBGHow we know
- A Phase I/II Study of [124I]mIBG PET/CT in NeuroblastomaCompletedPhase 1/2Cancer Research UKNCT02043899Written as [124I]meta-IodobenzylguanidineHow we know
- Haploidentical Stem Cell Transplantation in NeuroblastomaStatus unknownEarly Phase 1Lund University HospitalNCT00790413Written as iodine I 131 metaiodobenzylguanidineHow we know
- High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed NeuroblastomaCompletedPhase 1University of California, San FranciscoNCT01313936Written as Metaiodobenzylguanidine (MIBG)How we know
- High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine TumorsCompletedPhase 3M.D. Anderson Cancer CenterNCT00037869Written as I-131 MetaiodobenzylguanidineHow we know
- N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk NeuroblastomaCompletedPhase 2Molecular Insight Pharmaceuticals, Inc.NCT00659984Written as UltratraceTM Iobenguane I 131 ImagingHow we know
- Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaCompletedPhase 1/2Molecular Insight Pharmaceuticals, Inc.NCT00458952Written as Ultratrace Iobenguane (MIBG) I 131How we know
- CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II StudyStatus unknownPhase 2National Center for Research Resources (NCRR)NCT00013806Written as 131I-MIBGHow we know
Given beside what is tested · 2 — 3-Iodobenzylguanidine is usual care or a partner of the new treatment
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + DinutuximabNot yet recruitingPhase 2New Approaches to Neuroblastoma Therapy ConsortiumNCT07261241Written as Radiation: 131I-MIBGHow we know
- Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine TumorsCompletedEarly Phase 1University of Michigan Rogel Cancer CenterNCT04510311Written as [123I] metaiodobenzylguanidineHow we know
Codes
What other systems call 3-Iodobenzylguanidine · ClinicalTrials.gg INT008719
- MeSH (NLM) D0197973-IodobenzylguanidineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 35MRW7B4ADIOBENGUANEConfirmed FDA, NLM
- RxNorm 14448One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D019797 | 3-Iodobenzylguanidine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 35MRW7B4AD | IOBENGUANE | Confirmed FDA, NLM |
| RxNorm | 14448 | — | One source FDA |
Also registered as iobenguane i-131 (UNII Q461L7AK4R · RxNorm 2053281).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.